Nutex Health Gelecekteki Büyüme
Future kriter kontrolleri 3/6
Nutex Health kazanç ve gelirinin sırasıyla yıllık 32.1% ve 6% oranında artması tahmin edilirken, EPS'nin yıllık 22.9% oranında büyümesi bekleniyor.
Anahtar bilgiler
32.1%
Kazanç büyüme oranı
22.93%
EPS büyüme oranı
| Healthcare kazanç büyümesi | 18.4% |
| Gelir büyüme oranı | 6.0% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 13 May 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Anlatı Güncellemesi • May 09
NUTX: Share Repurchases Will Support Future Margins And Upside Potential
Analysts now place Nutex Health's fair value at $175.00, up from $150.00, citing updated assumptions around revenue growth of 5.25%, a profit margin of 21.15%, a discount rate of 7.19% and a forward P/E of 7.95. What's in the News On March 5, 2026, the Board of Directors authorized a share buyback plan for Nutex Health.Anlatı Güncellemesi • Apr 23
NUTX: Share Repurchases Will Support Future Margins And Undervalued Upside
Analysts reaffirm a $150.00 price target for Nutex Health, citing updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a small change in future P/E multiples as key inputs to their valuation work. What's in the News Nutex Health Inc.Anlatı Güncellemesi • Apr 09
NUTX: New Buyback Program Will Support Future Margin Resilience
Analysts have raised their Nutex Health price target to $150.00 as they now factor in slightly stronger revenue growth, a modestly higher profit margin of about 18.6%, and a marginally lower future P/E assumption near 8x. What's in the News From October 1, 2025 to December 31, 2025, Nutex Health repurchased 27,870 shares, about 0.4% of its stock, for US$4.95 million under a previously announced buyback program (Key Developments).
Anlatı Güncellemesi • Mar 25
NUTX: Share Repurchases Will Support Future Upside Potential
Analysts have adjusted their price target on Nutex Health from $241.67 to $221.67, reflecting updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Nutex Health completed a previously announced buyback program, repurchasing 27,870 shares, representing 0.4% of the company, for a total of $4.95 million between October 1, 2025 and December 31, 2025 (Key Developments).Anlatı Güncellemesi • Mar 11
NUTX: New Hospitals And Buybacks Will Support Future Margin Resilience
Analysts have adjusted their price target on Nutex Health to $150 from $220, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Nutex Health Inc.Anlatı Güncellemesi • Feb 25
NUTX: Expanded Hospital Footprint Will Support Future Margin Resilience
Analysts have kept their $220.00 price target for Nutex Health unchanged, citing relatively steady assumptions for the discount rate, long-term revenue growth, profit margin, and future P/E expectations. What's in the News Nutex Health announced the opening of its 26th hospital, Archview ER & Hospital, in a new state, Missouri, expanding its footprint into St. Louis for the first time (Key Developments).Anlatı Güncellemesi • Feb 11
NUTX: Future Margin Resilience Will Outlast Fraud Allegations And Filing Delay
Analysts have maintained their Nutex Health fair value estimate at $220.00. They cite small adjustments to the discount rate, revenue growth, profit margin, and expected future P/E assumptions, rather than any major change in their overall view.Anlatı Güncellemesi • Jan 27
NUTX: Future Margin Strength Will Outweigh Fraud Allegation And Filing Risk
Analysts have kept their price target on Nutex Health steady at US$220.00, citing slightly higher modeled revenue growth, a modestly improved profit margin and a marginally lower forward P/E assumption as key reasons for maintaining their view. What's in the News Short seller Capybara Research published a report alleging that Nutex Health and its founder CEO engaged in fraudulent and unethical business practices, citing interviews with former insiders and partners and claiming a pattern of misconduct over about 10 years (Periodical).Anlatı Güncellemesi • Jan 12
NUTX: Future Margin Strength Will Offset Fraud Allegation Headwinds
Analysts have slightly revised their price target on Nutex Health to US$220, reflecting modestly updated assumptions around revenue, profit margins, and future P/E expectations. What's in the News Capybara Research published a report alleging Nutex Health and its CEO engaged in fraudulent and unethical business practices over a period of about 10 years.Anlatı Güncellemesi • Dec 26
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Analysts have modestly raised their price target on Nutex Health to approximately 220 dollars per share, citing slightly stronger anticipated revenue growth and profit margins. These factors support a marginally lower future price to earnings multiple.Anlatı Güncellemesi • Dec 12
NUTX: Margin Expansion Will Drive Future Upside Despite Fraud Allegations
Narrative Update on Nutex Health Analysts have raised their price target on Nutex Health from 205.00 dollars to 220.00 dollars, reflecting expectations for meaningfully improved profit margins and a more favorable future earnings multiple, despite moderating revenue growth assumptions and a slightly lower discount rate. What's in the News Capybara Research issued a report alleging Nutex Health and its CEO engaged in a long running pattern of fraudulent and unethical business practices, and warned that more physician groups and emergency rooms may sever ties with the company (Capybara Research report).Seeking Alpha • Sep 10
Nutex: Diagnosed With A Case Of Fair Value
Summary Nutex Health shows strong revenue growth and a healthy balance sheet, but recent issues with SEC filings and a short report caused the stock to decline. Growth prospects hinge on the execution of expansion, especially in the IPA segment, which could drive future cash flow at low cost. Competitive pressures, cyclical capex, and significant stock-based compensation limit upside and warrant a deeper margin of safety for investors. At current levels, NUTX is not undervalued; I recommend a Hold rating and would only consider buying below $65 for better risk-reward. Read the full article on Seeking AlphaYeni Anlatı • May 28
Aging US Population Will Drive Micro-Hospital Expansion Despite Payer Challenges
Expansion in key markets and value-focused care models align Nutex with demographic trends and rising demand for accessible, cost-effective healthcare.Analiz Makalesi • Jan 24
Health Check: How Prudently Does Nutex Health (NASDAQ:NUTX) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Dec 25
Nutex Health Inc. (NASDAQ:NUTX) Might Not Be As Mispriced As It Looks
When close to half the companies operating in the Healthcare industry in the United States have price-to-sales ratios...Analiz Makalesi • Aug 12
Nutex Health Inc. (NASDAQ:NUTX) Just Reported, And Analysts Assigned A US$2.75 Price Target
The analysts might have been a bit too bullish on Nutex Health Inc. ( NASDAQ:NUTX ), given that the company fell short...Analiz Makalesi • Apr 17
Nutex Health Inc.'s (NASDAQ:NUTX) 30% Cheaper Price Remains In Tune With Revenues
Unfortunately for some shareholders, the Nutex Health Inc. ( NASDAQ:NUTX ) share price has dived 30% in the last thirty...Seeking Alpha • Aug 23
Nutex Health GAAP EPS of -$0.03, revenue of $58.05M
Nutex Health press release (NASDAQ:NUTX): Q2 GAAP EPS of -$0.03. Revenue of $58.05M (-7.6% Y/Y). Adjusted EBITDA of $9.4M. As of June 30, 2022, the company had total assets of $871.8M, including cash and cash equivalents of $47.6M.Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2027 | 972 | 179 | 12 | 47 | 3 |
| 12/31/2026 | 883 | 155 | 9 | 39 | 3 |
| 3/31/2026 | 880 | 96 | 265 | 273 | N/A |
| 12/31/2025 | 875 | 71 | 241 | 248 | N/A |
| 9/30/2025 | 981 | 121 | 174 | 178 | N/A |
| 6/30/2025 | 792 | 56 | 81 | 85 | N/A |
| 3/31/2025 | 624 | 74 | 69 | 71 | N/A |
| 12/31/2024 | 480 | 52 | 21 | 23 | N/A |
| 9/30/2024 | 292 | -41 | 20 | 21 | N/A |
| 6/30/2024 | 276 | -38 | 13 | 17 | N/A |
| 3/31/2024 | 259 | -41 | -3 | 3 | N/A |
| 12/31/2023 | 248 | -46 | -8 | 1 | N/A |
| 9/30/2023 | 232 | -29 | 5 | 8 | N/A |
| 6/30/2023 | 197 | -436 | -7 | -2 | N/A |
| 3/31/2023 | 196 | -451 | 6 | 16 | N/A |
| 12/31/2022 | 219 | -425 | 36 | 51 | N/A |
| 9/30/2022 | 229 | -396 | 58 | 93 | N/A |
| 6/30/2022 | 319 | 70 | 92 | 124 | N/A |
| 3/31/2022 | 336 | 122 | 123 | 158 | N/A |
| 12/31/2021 | 332 | 133 | 137 | 173 | N/A |
| 9/30/2021 | 374 | 159 | 94 | 160 | N/A |
| 12/31/2020 | 274 | 106 | 25 | 87 | N/A |
| 12/31/2019 | 97 | 21 | N/A | 12 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: NUTX 'nin tahmini kazanç büyümesi (yıllık 32.1% ) tasarruf oranının ( 3.5% ) üzerindedir.
Kazançlar ve Piyasa: NUTX şirketinin kazançlarının (yıllık 32.1% ) US pazarından (yıllık 16.8% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: NUTX şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.
Gelir ve Pazar: NUTX şirketinin gelirinin (yıllık 6% ) US pazarından (yıllık 11.7% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Geliri: NUTX şirketinin gelirinin (yıllık 6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: NUTX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 04:46 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Nutex Health Inc. 4 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| William Sutherland | Benchmark Company |
| Eugene Mannheimer | Freedom Capital Markets |
| Anthony Vendetti | Maxim Group |